A biotechnology company focused on developing oral small‑molecule therapies for rare diseases, with a commercial product targeting hereditary angioedema. Revenue is driven primarily by Orladeyo, a once‑daily oral prophylactic treatment, while the pipeline includes additional programs in complement‑m...
2 members of Congress have disclosed 4 trades in BioCryst Pharmaceuticals, Inc. (BCRX), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-11-13 | Gilbert Cisneros | buy | $1K – $15K |
| 2023-10-16 | Josh Gottheimer | buy | $1K – $15K |
| 2023-09-15 | Josh Gottheimer | sell | $1K – $15K |
| 2022-08-11 | Josh Gottheimer | buy | $1K – $15K |